Skip to main content
. Author manuscript; available in PMC: 2014 Aug 5.
Published in final edited form as: Addiction. 2011 Nov 15;107(2):361–369. doi: 10.1111/j.1360-0443.2011.03619.x

Table 1.

Baseline characteristics of the experimental and placebo medication groups.

Medication groups
Characteristic Experimental (n = 56) Placebo (n = 55) P-value
Mean age (years) (SD) 40.77 (7.46) 35.98 (8.75) 0.0033
Gender (%) Male 80 75 NS
Ethnicity: (%) White 65.4 55.4 NS
Hispanic (all) 21.8 37.4
Black 9.1 5.4
Marital status (%) Married 20.0 21.4 NS
Widowed/divorced/separated 16.4 17.9
Never married 63.6 60.7
Employment (%) Full time 58.2 53.6 NS
Part-time 18.2 32.1
Unemployed 20.0 10.7
Other 3.6 3.6
Criminal justice status On probation/parole (%) 89.1 82.1 NS
Has criminal history (%) 43.6 33.9 NS
Abuse history Physically abused (%) 60.0 57.1 NS
Sexually abused (%) 69.1 75.0 NS
Drug treatment/drug use/craving Mean no. of treatments 1.69 (2.76) 2.02 (5.40) NS
Mean no. of days amphetamine/methamphetamine
    Use in past 30 days 17.82 (9.90) 17.13 (9.45) NS
    Mean years of use 10.84 (8.18) 9.66 (6.60) NS
    Mean craving (BSCS) 6.62 (2.91) 6.59 (2.93) NS

BSCS: The Brief Symptom Craving Scale; SD: standard deviation; NS: not significant. [Correction added after online publication 7 December 2011; amphetamine/methadone has been changed to amphetamine/methamphetamine].